Download Overcoming Ovarian Cancer Chemoresistance Book PDF

Download full Overcoming Ovarian Cancer Chemoresistance books PDF, EPUB, Tuebl, Textbook, Mobi or read online Overcoming Ovarian Cancer Chemoresistance anytime and anywhere on any device. Get free access to the library by create an account, fast download and ads free. We cannot guarantee that every book is in the library.

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
  • Author : Goli Samimi,Christina Annunziata
  • Publisher :Unknown
  • Release Date :2020-11-06
  • Total pages :188
  • ISBN : 9780128198414
GET BOOK HERE

Summary : Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2021-07-15
  • Total pages :300
  • ISBN : 012824299X
GET BOOK HERE

Summary : Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
  • Author : Andrew Freywald,Franco Vizeacoumar
  • Publisher :Unknown
  • Release Date :2020-12-04
  • Total pages :308
  • ISBN : 9780128213117
GET BOOK HERE

Summary : Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Cancer Drug Resistance Research Perspectives

Cancer Drug Resistance Research Perspectives
  • Author : Liman S. Torres
  • Publisher :Unknown
  • Release Date :2007
  • Total pages :223
  • ISBN : 1600215726
GET BOOK HERE

Summary : One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.

Development of a Patient-derived Xenograft Model of Ovarian Cancer to Characterize the Chemotherapy Resistant Population

Development of a Patient-derived Xenograft Model of Ovarian Cancer to Characterize the Chemotherapy Resistant Population
  • Author : Zachary Christopher Dobbin
  • Publisher :Unknown
  • Release Date :2014
  • Total pages :131
  • ISBN : OCLC:976010431
GET BOOK HERE

Summary : Ovarian cancer while the second most common gynecologic malignancy is the most commons cause of death due to a gynecologic malignancy and the fifth most common cause of death to cancer in women. In 2014, there will be an expected 21,980 cases and 14,270 deaths. Unfortunately, the five-year survival for ovarian cancer is only 40% and this has barely increased over the past 30 years. New approaches need to be developed in order to study ovarian cancer and identify methods of overcoming chemotherapy resistance. This dissertation presents the work conducted in the development of a patient-derived xenograft model of ovarian cancer to characterize the chemotherapy resistant population and identify novel methods of targeting ovarian cancer. The ovarian cancer patient-derived xenograft model recapitulates the heterogeneity of the patients’ tumor and has demonstrated clinical relevance in response to primary therapy. Using RNA-seq, it was identified that ribosomal synthesis was upregulated and targeting RNA Polymerase I is a potential method of overcoming chemotherapy resistance. Using a patient-derived xenograft model provides a novel platform for understanding chemotherapy resistance and recurrence in ovarian cancer.

Ovarian Cancers

Ovarian Cancers
  • Author : National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Care Services,Committee on the State of the Science in Ovarian Cancer Research
  • Publisher :Unknown
  • Release Date :2016-05-25
  • Total pages :396
  • ISBN : 9780309380461
GET BOOK HERE

Summary : In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher :Unknown
  • Release Date :2019-07-15
  • Total pages :320
  • ISBN : 9783030214777
GET BOOK HERE

Summary : Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

The Tumor Microenvironment of High Grade Serous Ovarian Cancer

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
  • Author : M. Sharon Stack,Kenneth P. Nephew,Joanna E. Burdette,Anirban K. Mitra
  • Publisher :Unknown
  • Release Date :2019-02-06
  • Total pages :434
  • ISBN : 9783038975540
GET BOOK HERE

Summary : This book is a printed edition of the Special Issue "The Tumor Microenvironment of High Grade Serous Ovarian Cancer" that was published in Cancers

Targeting Ovarian Cancer Through Epigallocatechin Gallate and Sulforaphane Combinatorial Treatment

Targeting Ovarian Cancer Through Epigallocatechin Gallate and Sulforaphane Combinatorial Treatment
  • Author : Huaping Chen
  • Publisher :Unknown
  • Release Date :2013
  • Total pages :172
  • ISBN : OCLC:858924909
GET BOOK HERE

Summary : The cellular development of resistance to chemotherapy contributes to the high mortality noted in patients affected by ovarian cancer. Novel compounds that can enhance efficacy of conventional chemotherapy or target both drug-sensitive and -resistant ovarian cancers directly are highly desired. Previous epidemiological studies indicate that consumption of green tea and cruciferous vegetables is inversely associated with occurrence of ovarian cancer. Therefore, revealing the effects and mechanisms of major components of green tea (epigallocatechin gallate, EGCG) and cruciferous vegetables (sulforaphane, SFN) on ovarian cancer cells will provide necessary knowledge for developing potential novel treatments for the disease. Since drug resistance generation is related to alterations of multiple cell survival pathways besides changes in pharmacokinetic pathways, combinational treatment targeting multiple pathways simultaneously is a promising strategy for therapy of drug-resistant ovarian cancer. In this study, EGCG or SFN was administered alone or in combination to treat both cisplatin/paclitaxel-sensitive and -resistant ovarian cancer cell lines. We found that SFN inhibits cell viability of both ovarian cancer cell lines time- and dose-dependently and EGCG can potentiate the inhibiting effect of SFN. In cisplatin-sensitive and -resistant ovarian cancer cells, SFN can arrest cancer cells in G2/M phase, and EGCG can enhance the SFN-mediated G2/M phase arresting effect. Furthermore, EGCG and SFN combinational treatment can enhance cisplatin-mediated apoptosis in cisplatin-sensitive and -resistant ovariance cancer cells through enhancing G2/M phase arrest and p21 upregulation. In paclitaxel-resistant ovarian cancer cells, SFN can induce cancer cells to undergo apoptosis, while EGCG can enhance SFN-mediated apoptosis. SFN can arrest both paclitaxel-sensitive and -resistant ovarian cancer cells in G2/M phase. However, EGCG and SFN combinational treatment can arrest more cells in S phase but fewer cells in G2/M phase. On molecular level, SFN can down-regulate hTERT and Bcl-2 while upregulating phosphorylated H2AX and cleaved poly(ADP-ribose) polymerase (PARP) which is a indicator for apoptosis. EGCG can enhance these SFN-mediated effects. Taken together, these results indicate that EGCG can potentiate SFN-mediated inhibiting effect on both cisplatin/paclitaxel-sensitive and -resistant ovarian cancer cell lines and suggest the use of these compounds for overcoming cisplatin/paclitaxel-resistance in ovarian cancer treatment.

Reversal of Drug Resistance in Non-Hodgkin's Lymphoma by Immunotherapy

Reversal of Drug Resistance in Non-Hodgkin's Lymphoma by Immunotherapy
  • Author : Steve Anthony Alas
  • Publisher :Unknown
  • Release Date :2000
  • Total pages :344
  • ISBN : UCLA:L0081786006
GET BOOK HERE

Summary :

A Woman's Guide to Overcoming Sexual Fear & Pain

A Woman's Guide to Overcoming Sexual Fear & Pain
  • Author : Aurelie Jones Goodwin,Marc E. Agronin
  • Publisher :Unknown
  • Release Date :1997
  • Total pages :280
  • ISBN : UOM:39015053169556
GET BOOK HERE

Summary : Explores the reasons for sexual disorders and advises when professional help is necessary

Heparanase

Heparanase
  • Author : Israel Vlodavsky,Ralph D. Sanderson,Neta Ilan
  • Publisher :Unknown
  • Release Date :2020-04-09
  • Total pages :885
  • ISBN : 9783030345211
GET BOOK HERE

Summary : Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology.

American Book Publishing Record

American Book Publishing Record
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2006
  • Total pages :229
  • ISBN : UOM:39015066180434
GET BOOK HERE

Summary :

Your Life in Your Hands

Your Life in Your Hands
  • Author : Jane A. Plant
  • Publisher :Unknown
  • Release Date :2007
  • Total pages :525
  • ISBN : 9780753512043
GET BOOK HERE

Summary : "Professor Jane Plant s international bestseller on combating breast cancer through diet and lifestyle changes has been fully revised and updated, including new information on ovarian cancer and other types of cancer. In this groundbreaking book, Professor Plant details her own experiences of suffering with breast cancer, and how she learnt of the relationship between the disease and diet. The book explains the science behind the no dairy diet and gives practical advice on how diet and lifestyle changes can help prevent and overcome breast and ovarian cancer. For sufferers, their families and anyone who is concerned about the risk of cancer, this book is essential reading."

PIPAC

PIPAC
  • Author : Marc A. Reymond,Wiebke Solass
  • Publisher :Unknown
  • Release Date :2014-10-14
  • Total pages :252
  • ISBN : 9783110366617
GET BOOK HERE

Summary : Peritoneal dissemination is a common route of cancer metastasis. The benefit of administering chemotherapy directly into the peritoneal cavity is supported by preclinical and pharmacokinetic data. In comparison to intravenous (IV) treatment, intraperitoneal (IP) administration results in a several-fold increase in drug concentration within the abdominal cavity. There is now growing evidence from clinical studies showing a survival advantage for IP chemotherapy in various tumor typies, including ovarian, gastric and colorectal cancer. However, while the use of IP chemotherapy is slowly gaining acceptance, it is not universal, largely due to the greater toxicity associated with this approach. Moreover, efficacy of IP chemotherapy is limited by poor distribution within the abdominal cavity and by poor tissue penetration. A new way of IP chemotherapy is the application of cytotoxics in form of a pressurized aerosol into the abdominal of thoracic cavity. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is applied through laparoscopic access using two balloon trocars in an operating room equipped with laminar air-flow. In a first step,a normothermic capnoperitoneum is established with a pressure of 12 mmHg. A cytotoxic solution (about 10% of a normal systemic dose) is nebulized with a micropump into the abdominal cavity, and maintained for 30 min. The aerosol is then removed through a closed suction system. Applying an aerosol in the peritoneal cavity allows a homogeneous distribution of the chemotherapeutic agent within the abdomen. Furthermore, an artificial pressure gradient is generated that overcomes tumoral interstitial fluid pressure, an obstacle in cancer therapy. This results in a higher local drug concentration compared to conventional IP or IV chemotherapy. At the same time the plasma concentration of the chemotherapeutic agent remains low. In first clinical studies with limited number of patients in ovarian, gastric and colorectal cancer, as well as peritoneal mesothelioma, PIPAC has obtained encouraging tumor response rates and survival, with a low-side effects profile. Larger clinical trials are currently ongoing to examine if these data can be reproduced and extrapolated to other situations.

Role of Nutraceuticals in Cancer Chemosensitization

Role of Nutraceuticals in Cancer Chemosensitization
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2017-10-18
  • Total pages :398
  • ISBN : 9780128123744
GET BOOK HERE

Summary : Role of Nutraceuticals in Chemoresistance to Cancer, Volume Two, focuses on nutraceuticals, the compounds derived from natural sources, which are usually multi-targeted as a means to overcome chemoresistance. This book discusses the role of several compounds related to nutraceuticals and chemoresistance, such as curcumin, resveratrol, indole 3-carbinol, tocotrienols, ursolic acid, fisetin, celastrol, gambogic, butein, catechins and silymarin. It is a valuable resource for cancer researchers, oncologists and members of several areas of the biomedical field who are interested in understanding how to use nutraceuticals as a sensitizing agent for chemotherapy. Brings updated information on natural compounds used as specific inhibitors of cell signaling pathways as reviewed by experts in the field Presents experts analysis and summary of reported and novel findings and potential translational application in cancer patients Describes molecular mechanisms with new and helpful approaches for the readers to use in their own investigations

Ovarian Cancer

Ovarian Cancer
  • Author : Chris E. Newman,C. H. J. Ford,Joseph A. Jordan
  • Publisher :Unknown
  • Release Date :1980
  • Total pages :249
  • ISBN : UOM:39015010658329
GET BOOK HERE

Summary : Hardbound. Internationally recognised experts have contributed individual chapters on a variety of topics ranging from histopathology through surgical, radiotherapeutic and chemotherapeutic treatment modalities to in vitro sensitivity testing and epidemiology. The book, therefore, presents a broad based review of current achievements and will be of interest to all those with an interest in ovarian cancer, including clinicians, epidemiologists and research workers. Topic orientated panel discussions and questions raised after delivery of individual papers have been included

Cancer Research

Cancer Research
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :1993
  • Total pages :229
  • ISBN : NWU:35558002984595
GET BOOK HERE

Summary :

Beating Ovarian Cancer

Beating Ovarian Cancer
  • Author : Chris Bledy
  • Publisher :Unknown
  • Release Date :2008
  • Total pages :224
  • ISBN : 1890427675
GET BOOK HERE

Summary : A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to healing.

Epigenetic Alterations in Oncogenesis

Epigenetic Alterations in Oncogenesis
  • Author : Adam R. Karpf
  • Publisher :Unknown
  • Release Date :2012-09-06
  • Total pages :348
  • ISBN : 9781441999672
GET BOOK HERE

Summary : The purpose of this book is to provide an up to date review of the nature and consequences of epigenetic changes in cancer. Epigenetics literally means “above” genetics, and consists of heritable gene expression or other phenotypic states not accounted for by DNA base sequence. Epigenetic changes are now known to make a large contribution to various aspects of tumorigenesis. These changes include alterations in global and promoter specific DNA methylation, activating and repressive histone modifications, and changes in higher order chromatin structures. Each of these topics will be covered in this book.

The Cancer Bulletin

The Cancer Bulletin
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :1986
  • Total pages :229
  • ISBN : NWU:35558001269881
GET BOOK HERE

Summary :